Catalog No.
Product Name
Application
Product Information
Citations
-
PAF Antagonist
SDZ-62-434 is a potent platelet-activating factor (PAF) antagonist. It exhibits significant antiproliferative activity against various human solid tumors and hematological malignancies. This compound is useful for research focused on cancer biology, inflammation, and related therapeutic applications. -
PAF Homolog
2-O-Ethyl PAF C-16 is a homolog of platelet-activating factor (PAF) and acts as a competitive ligand for the platelet-activating factor receptor (PAFR). It exhibits significant inhibition of PAF receptor binding, demonstrated by an IC50 value of 21 nM against the PAF antagonist WEB 2086. This compound is useful for studying PAF-related signaling pathways and the physiological effects mediated by PAFR in various biological research applications. -
Platelet-activating Factor Receptor (PAFR) Inhibitor
Dersalazine is a selective inhibitor of the platelet-activating factor receptor (PAFR), demonstrating significant intestinal anti-inflammatory properties. This compound shows potential efficacy in the treatment of ulcerative colitis, making it a valuable tool for research into inflammatory bowel diseases. Its ability to modulate PAFR-mediated signaling pathways makes Dersalazine a pertinent candidate for exploring therapeutic strategies targeting inflammation and related gastrointestinal disorders. -
Platelet-activating Factor Antagonist
Ro 19-1400 is a platelet-activating factor antagonist that inhibits immunoglobulin E-dependent mediator release. This compound is effective in blocking the actions of platelet-activating factor (PAF), a phospholipid that plays a crucial role in inflammatory processes. Ro 19-1400 is primarily utilized in studies exploring allergic responses and inflammation, making it valuable for research applications aimed at understanding and developing treatments for allergies and related conditions. -
PAF Receptor Antagonist
L 651142 is a weak antagonist of the platelet activating factor (PAF) receptor. This compound effectively inhibits the binding of [3H]PAF to membranes derived from rabbit platelets, human platelets, and human lung tissues, with inhibition constants (Kis) of 0.839 μM, 1.82 μM, and 3.64 μM, respectively. L 651142 is utilized in research applications that explore the role of PAF in physiological and pathological processes, making it valuable for studies related to inflammation, thrombosis, and respiratory function. -
Platelet-activating Factor Receptor (PAFR) Antagonist
ABT-299 is a prodrug that functions as an antagonist of the platelet-activating factor receptor (PAFR). It demonstrates notable inhibitory activity on PAF-induced β-platelet globulin release in vitro following administration in humans, a mechanism that may involve its metabolite, pyridine-N-oxide. This compound is of particular interest for research into inflammatory responses and platelet activation processes. -
PAF Inhibitor
CV 3988 is a selective inhibitor of platelet-activating factor (PAF), a lipid mediator involved in various inflammatory processes. By blocking PAF activity, CV 3988 demonstrates potential in mitigating inflammation-related pathways and may be valuable in studying conditions influenced by PAF. This compound is suitable for research applications in inflammation, cardiovascular diseases, and related areas of biochemical investigation. -
PAFR Inhibitor
Piperulin A is a selective inhibitor of the platelet-activating factor receptor (PAFR). It effectively disrupts the specific binding of PAFR on isolated rabbit platelet plasma membranes, demonstrating an IC50 value of 7.3 μM. This compound is valuable for research applications focused on understanding PAFR-related signaling pathways and their implications in various physiological and pathological processes. -
PAF Inhibitor
Pinusolidic acid is an inhibitor of platelet-activating factor (PAF), demonstrating an IC50 value of 23 μM. This compound is primarily utilized in research to study the roles of PAF in various biological processes and diseases, including inflammation and thrombosis. Its inhibitory properties make it a valuable tool for investigating PAF-related pathways and potential therapeutic applications. -
Platelet Aggregation Inhibitor
Aggreceride A is a potent platelet aggregation inhibitor that targets multiple pathways involved in thrombosis. It exhibits significant inhibitory activity against platelet aggregation induced by Adenosine 5'-diphosphate (ADP), arachidonic acid, and platelet-activating factor (PAF), making it valuable for cardiovascular research. However, it demonstrates reduced efficacy against collagen-induced aggregation. This compound is suitable for studying mechanisms of platelet function and the effects of aggregation inhibitors in various therapeutic contexts. -
PAF Inhibitor
BN 52111 is a potent platelet-activating factor (PAF) receptor antagonist. It inhibits PAF signaling, which plays a crucial role in various physiological processes, including inflammation and thrombosis. BN 52111 is primarily utilized in research applications to investigate the role of PAF in disease models and to explore potential therapeutic interventions. -
PAF Antagonist
L662,025 is a potent and irreversible antagonist of the platelet-activating factor (PAF) receptor. It demonstrates a strong binding affinity with an IC50 value of 1 μM for receptor binding and effectively inhibits platelet aggregation at an IC50 value of 5.6 μM. This compound is primarily utilized in research applications focused on delineating the biological roles of PAF in various physiological and pathological processes. -
Platelet Aggregation Inhibitor
Aggreceride B is a potent platelet aggregation inhibitor targeting pathways involved in thrombus formation. It effectively inhibits platelet aggregation induced by Adenosine 5'-diphosphate (ADP), arachidonic acid, and platelet activating factor (PAF), while demonstrating reduced activity against collagen-induced aggregation. This compound is valuable in studies focused on thromboembolic diseases and platelet function analysis. -
Antiplatelet Aggregation Agent
Oxopurpureine is an oxoaporphine that functions as an antiplatelet aggregation agent. It effectively inhibits platelet aggregation induced by collagen, thrombin, and arachidonic acid. This compound is valuable for research applications focused on hemostasis, thrombosis, and related cardiovascular studies. -
PAF Antagonist
Kadsurenin B is a potent antagonist of platelet-activating factor (PAF), exhibiting notable neuroprotective properties. This compound is of significant interest in pharmacological research due to its diverse biological activities, including antibacterial, anti-inflammatory, antioxidant, antiplatelet aggregation, cytotoxic, and antiparasitic effects. Kadsurenin B may be utilized in various applications, making it valuable for studies focused on neuroprotection and inflammation modulation. -
PAF Antagonist
TCV-309 is a potent antagonist of platelet-activating factor (PAF). It demonstrates protective effects on cardiac function, particularly during ischemia-reperfusion, with significant improvement in left ventricular function observed (77.6% recovery at 1 μM). This compound is valuable for research applications involving cardiovascular disease and related ischemic conditions. -
PAF Receptor Antagonist
Minopafant is a potent antagonist of the platelet-activating factor (PAF) receptor. It demonstrates significant biological activity by inhibiting PAF-mediated signaling pathways, which are implicated in various pathological conditions. This compound is primarily utilized in research focused on cerebral vasospasm, particularly following subarachnoid hemorrhage, providing insights into its therapeutic potential and underlying mechanisms. -
Platelet Activating Factor Antagonist
ONO-6240 is a potent antagonist of platelet-activating factor (PAF), which plays a critical role in inflammatory responses. This compound effectively inhibits eosinophil infiltration in the airways, making it a valuable tool for researching asthma and other pulmonary conditions. Its ability to modulate PAF activity positions ONO-6240 as an important candidate for studies aimed at understanding and treating allergic and inflammatory diseases. -
Platelet Aggregation Inhibitor
Aggreceride C is a potent platelet aggregation inhibitor targeting multiple pathways involved in platelet activation. It effectively inhibits aggregation induced by Adenosine 5'-diphosphate (ADP), arachidonic acid, and platelet activating factor (PAF) while demonstrating reduced activity against collagen-induced aggregation. This compound is valuable for research applications focused on thrombosis and vascular biology. -
Platelet-activating Factor Receptor (PAFR)
PAF-AN-1 is a selective antagonist of the platelet-activating factor receptor (PAFR). It inhibits PAF-mediated signaling pathways, demonstrating the ability to modulate inflammation and allergic responses. PAF-AN-1 is utilized in research applications focused on cardiovascular diseases, asthma, and other conditions driven by PAF activity. -
PK2 Antagonist
PKRA83 is a potent antagonist of prokineticin 2 (PK2), functioning by competing for binding sites on PKR1 and PKR2 receptors. It demonstrates significant inhibition of PK2, with IC50 values of 5.0 nM for PKR1 and 8.2 nM for PKR2. PKRA83 exhibits various biological activities, including anticancer, anti-arthritis, and anti-angiogenic effects, making it valuable for research applications in cancer biology, inflammatory diseases, and angiogenesis studies. -
PKR1 Antagonist
PKR1 antagonist 1 is a selective antagonist of the PKR1 receptor, which plays a crucial role in pain signaling. This compound has demonstrated efficacy in reducing hyperalgesia and allodynia in the spared nerve injury (SNI) mouse model. Its application is significant for research focused on pain management and the underlying mechanisms of nociceptive signaling. -
PKR2 Antagonist
A457 is a selective antagonist of the prokineticin receptor PKR2, exhibiting an IC50 value of 102 nM. This compound effectively restores cell surface expression and functionality of the P290S PKR2 variant, while showing no activity against the W178S and G234D PKR2 mutations. A457 is valuable for research applications focused on the modulation of PKR2-related pathways and the study of receptor mutations. -
TXA2 Agonist
U-46619 is a stable analogue of Thromboxane A2 (TXA2) that functions as a potent TXA2 receptor (TP) agonist. This compound also acts as a RhoA agonist, promoting RhoA activation through TXA2 receptor engagement. U-46619 is primarily utilized in research to study thromboxane signaling and its implications in cardiovascular and inflammatory responses. Its ability to selectively activate TXA2 pathways makes it an essential tool for investigating related biological processes. -
Prostaglandin
Prostaglandin D2 (PGD2) is an endogenous lipid mediator primarily involved in sleep promotion and the modulation of inflammatory responses. It is produced in various mammalian brains and is recognized for its potent ability to induce sleep and reduce inflammatory processes. PGD2 is valuable in research applications related to sleep disorders, neurobiology, and inflammation. -
Thromboxane-Prostaglandin Receptor Antagonist
Terutroban sodium is a selective and orally active thromboxane-prostaglandin (TP) receptor antagonist, exhibiting an IC50 value of 16.4 nM. This compound effectively inhibits the activity of thromboxane A2 (TXA2) and prostaglandin endoperoxide receptors, demonstrating potent antithrombotic effects. Terutroban sodium also possesses anti-atherosclerotic and anti-vasoconstrictor properties, making it valuable for research applications in cardiovascular disease and related areas. -
PGDS Inhibitor
2-Benzoylthiophene is a selective inhibitor of human hematopoietic prostaglandin D2 synthase (H-PGDS), exhibiting an IC50 value of 11.4 μM. This compound is valuable for investigating the role of prostaglandin D2 in inflammatory diseases and related research applications. Its inhibitory action on H-PGDS provides a useful tool for exploring therapeutic strategies targeting inflammatory pathways. -
EP3 Receptor Antagonist
L-798106 is a potent and highly selective antagonist of the prostanoid EP3 receptor, exhibiting a Ki value of 0.3 nM. While it demonstrates micromolar activity at the EP4 receptor with a Ki of 916 nM, it shows minimal binding affinities at the EP1 and EP2 receptors, with Ki values exceeding 5000 nM. This compound is valuable for research applications involving the modulation of EP3 receptor-mediated pathways and investigating the role of prostanoids in various physiological processes. -
EP4 Receptor Agonist
L-902688 is a potent and selective agonist of the EP4 receptor, exhibiting a Ki value of 0.38 nM and an EC50 of 0.6 nM. This compound demonstrates greater than 4,000-fold selectivity for EP4 compared to other EP and prostanoid receptors. It serves as a valuable tool for researchers investigating the role of EP4 in various biological processes and potential therapeutic applications related to inflammation and pain management. -
EP4 Receptor Antagonist
L-161982 is a selective antagonist of the EP4 receptor, effectively inhibiting the biological activity of prostaglandin E2 (PGE2). It demonstrates complete blockade of PGE2-induced ERK phosphorylation and suppresses cell proliferation in HCA-7 cells. In addition, L-161982 has been shown to reduce symptoms of collagen-induced arthritis in murine models, making it a valuable tool for studying inflammatory pathways and potential therapeutic interventions in arthritis research. -
EP2 Receptor Agonist
Omidenepag is a selective, non-prostanoid agonist of the EP2 receptor, exhibiting an EC50 of 1.1 nM. With an IC50 value of 10 nM for the human EP2 receptor, Omidenepag plays a crucial role in studying conditions associated with intraocular pressure. Its potent biological activity makes it a valuable tool for research into ocular diseases and related pathophysiological mechanisms. -
Vasodilator
Beraprost sodium is a stable, orally active prostacyclin analog that acts as a potent vasodilator. By expanding renal blood vessels and enhancing microcirculation, it holds potential for the treatment of pulmonary arterial hypertension. Additionally, Beraprost sodium features an alkyne group, enabling its use as a click chemistry reagent that can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules, facilitating various biochemical applications. -
EP3 Receptor Agonist
Ricinoleic acid is a hydroxylated fatty acid and a potent agonist of the prostaglandin EP3 receptor, with an EC50 of 0.5 μM in MEG-01 cells. This compound is associated with various biological activities, including laxative effects and uterine contractions. Additionally, ricinoleic acid demonstrates both antianxiety-like and anti-inflammatory properties, making it valuable for research in pharmacology and developmental biology. Its high purity (≥99%) enhances its suitability for diverse applications, including studies related to gastrointestinal function and reproductive health. -
EP4 Antagonist
EP4 receptor antagonist 1 is a highly potent and selective competitive antagonist of the prostanoid EP4 receptor, primarily utilized in cancer immunotherapy. It exhibits strong inhibition of human and mouse EP4 receptors with IC50 values of 6.1 nM and 16.2 nM, respectively, while showing minimal activity against human EP1, EP2, and EP3 receptors, with IC50s exceeding 10 μM. This specificity makes it a valuable tool for investigating the role of EP4 in various oncological processes. -
PGD2 receptor Agonist
Prostaglandin J2 (PGJ2) is a potent agonist of the PGD2 receptors, notably hDP and hCRTH2, exhibiting Kis of 0.9 nM and 6.6 nM, respectively. It effectively stimulates intracellular cyclic AMP production with an EC50 of 1.2 nM. Beyond its receptor activity, Prostaglandin J2 is implicated in inducing oxidative stress, neuronal apoptosis, and the accumulation of ubiquitinated proteins. Its neurotoxic properties suggest a potential role in the pathogenesis of neurodegenerative diseases such as Alzheimer's and Parkinson's. This compound is valuable for research into receptor signaling pathways and neurodegenerative mechanisms. -
Prostaglandin Receptor Inhibitor
p-Hydroxycinnamic acid is a prostaglandin receptor inhibitor that functions as a dietary phenolic compound. It demonstrates significant biological activity by inhibiting platelet activity, with IC50 values of 371 μM for thromboxane B2 production and 126 μM for lipopolysaccharide-induced prostaglandin E2 generation. This compound is often utilized in research related to inflammation, cardiovascular diseases, and platelet function studies. -
Prostacyclin Agonist
ONO 1301 is a potent prostacyclin agonist that mimics the action of prostaglandin I2. It exhibits thromboxane-synthase inhibitory activity, enhancing the production of hepatocyte growth factor (HGF) from multiple cell types. Research demonstrates that ONO 1301 effectively ameliorates ischemia-induced left ventricular dysfunction in various animal models, including mouse, rat, and pig, making it a valuable tool for studies related to cardiovascular health and regenerative medicine. -
EP1 Antagonist
SC-51322 is a selective antagonist of the prostaglandin E2 receptor subtype EP1, exhibiting a pA2 value of 8.1. This compound demonstrates significant analgesic properties, making it a valuable tool for research focused on pain mechanisms and inflammation. Its specificity for the EP1 receptor allows for the exploration of pathways involved in nociception and potential therapeutic interventions. -
EP4 Agonist
Rivenprost is a selective agonist of the prostaglandin E receptor EP4, characterized by a Ki value of 0.7 nM. It has demonstrated hepatoprotective properties and bone anabolic activity. This compound is relevant for research in areas such as liver protection, bone metabolism, and the pharmacological modulation of EP4 receptor activity. -
EP2 Receptor Agonist
Omidenepag isopropyl is a selective agonist of the EP2 receptor. Upon corneal penetration, it is converted to the active form, Omidenepag, which demonstrates high selectivity for the EP2 receptor with minimal affinity for EP1 and FP receptors. This compound is under investigation for its potential use in lowering intraocular pressure, making it a valuable candidate for glaucoma treatment research. -
Prostaglandin Derivative
Thromboxane B2 is a prostaglandin derivative primarily involved in inducing arterial contraction and promoting platelet aggregation. This biological inactive product serves as a circulating catabolite of thromboxane A2, making it relevant as a diagnostic marker for angina in both peripheral venous and coronary sinus blood. Research indicates that Thromboxane B2 levels correlate with COX-1 activity inhibition in platelets. Furthermore, in preclinical models, Thromboxane B2 has demonstrated dose-dependent effects on respiratory function, producing decreases in airflow rate and dynamic lung compliance while increasing pulmonary airway resistance, highlighting its role as a bronchoactive metabolite in the arachidonic acid bioconversion pathway. -
CRTH2/DP Receptors Dual Antagonist
Vidupiprant is a phenylacetic acid derivative that acts as a dual antagonist of CRTH2 (DP2) and prostanoid D receptors (DP1). It exhibits high potency with IC50 values of 3 nM and 4 nM in buffer, and 8 nM and 35 nM in human plasma, respectively. This compound shows promise for therapeutic applications in asthma management and related respiratory conditions. -
TXA2 Receptor Antagonist
NTP42 is a potent thromboxane A2 (TXA2) receptor antagonist, exhibiting an IC50 of 3.278 nM in inhibiting T prostanoid receptor (TP)-mediated [Ca2+] mobilization upon stimulation with the alternative TP agonist U46619. This compound is particularly relevant for research applications targeting pulmonary arterial hypertension (PAH), offering potential therapeutic avenues for addressing this condition through TXA2 modulation. -
Dual Thromboxane Synthase Inhibitor and Receptor Antagonist
Ridogrel is a dual thromboxane A2 synthase inhibitor and receptor antagonist. This compound exhibits potent antiplatelet activity, making it useful in research focused on cardiovascular diseases and thrombotic disorders. Additionally, Ridogrel displays anti-inflammatory properties, providing a valuable tool for studying inflammation-related pathways in various biological contexts. -
Thromboxane-prostanoid (TP) Receptor Antagonist
SQ 29548 is a selective thromboxane-prostanoid (TP) receptor antagonist. This compound inhibits TP receptor signaling, which plays a critical role in various physiological and pathological processes, including vascular function, platelet aggregation, and inflammation. Its primary applications include research in cardiovascular diseases, thrombus formation, and the study of prostanoid biology. SQ 29548 serves as a valuable tool for investigating the therapeutic potential of modulating TP receptor activity. -
EP4 Antagonist
MF-766 is a potent and selective EP4 antagonist, exhibiting a Ki value of 0.23 nM. It functions as a full antagonist in functional assays, displaying an IC50 of 1.4 nM, which slightly increases to 1.8 nM in the presence of 10% human serum. This reagent is valuable for research related to cancer and inflammatory diseases, facilitating the exploration of EP4 pathways in therapeutic contexts. -
Prostaglandin Receptor Inhibitor
Ascorbyl tetra-2-hexyldecanoate is a lipophilic derivative of L-ascorbic acid that functions as a prostaglandin receptor inhibitor. This compound demonstrates protective effects on HaCaT keratinocytes, maintaining cell viability against UVB and oxidative stress while decreasing the production of inflammatory mediators IL-1α and prostaglandin E2 (PGE2). In vivo studies show that topical application enhances epidermal thickness, increases stratum corneum hydration, and improves skin texture, highlighting its potential for formulating skin whitening agents in cosmetic applications. -
EP4 Agonist
TCS 2510 is a selective agonist of the EP4 receptor, known for its potential to modulate various biological processes. This compound exhibits significant activity in the context of metabolic diseases, making it a valuable tool for research applications aimed at understanding the underlying mechanisms of these disorders. -
Active Metabolite of Misoprostol
Misoprostol acid is the active metabolite of Misoprostol, a synthetic analogue of prostaglandin E1 (PGE1). This compound is rapidly formed through de-esterification in the gastrointestinal tract following oral administration and is effective in preventing non-steroidal anti-inflammatory drug-induced gastric ulcers. Additionally, Misoprostol acid plays a significant role in obstetric applications, particularly in the induction of labor. -
EP3 Receptor Agonist
Sulprostone is a potent and selective agonist of the EP3 receptor, a critical target in various physiological processes. This prostaglandin E2 (PGE2) analog exhibits antiulcer and nonsteroidal abortifacient properties. Sulprostone is relevant for research applications focused on pregnancy termination and the management of hemorrhages during delivery.
